Multiple Neurohumoral Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much?

Journal of Cardiac Failure

Volumn 14, Issue 7, 2008, Pages 555-560

  Mak, George ^a   Murphy, Niamh F ^a   Ali, Akbar ^a   Walsh, Alison ^a   O'loughlin, Christina ^a   Conlon, Carmel ^a   McCaffrey, Dermot ^a   Ledwidge, Mark ^a   McDonald, Kenneth ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

ambulatory blood pressure monitoring; hypotension; Medication; outcome

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HOSPITAL READMISSION; HUMAN; HYPOTENSION; MALE; MORTALITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HUMANS; HYPOTENSION; KIDNEY; MALE; MYOCARDIAL ISCHEMIA; NEUROTRANSMITTER AGENTS; PATIENT READMISSION; PROSPECTIVE STUDIES; RECEPTORS, ANGIOTENSIN; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 49549088154     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.03.003     Document Type: Article

References (28)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 (1991) 293-302
3. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (1993) 821-828
4. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
5. Krum H., Roecker E.B., Mohacsi P., Rouleau J.L., Tendera M., Coats A.J., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289 (2003) 712-718
6. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357 (2001) 1385-1390
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353 (1999) 9-13
9. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
10. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
11. Remme W.J., Riegger G., Hildebrandt P., Komajda M., Jaarsma W., Bobbio M., et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 18 (2004) 57-66
12. Anand I., McMurray J., Cohn J.N., Konstam M.A., Notter T., Quitzau K., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 364 (2004) 347-354
13. Anand I.S., Tam S.W., Rector T.S., Taylor A.L., Sabolinski M.L., Archambault W.T., et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 49 (2007) 32-39
14. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
15. Packer M., Califf R.M., Konstam M.A., Krum H., McMurray J.J., Rouleau J.L., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002) 920-926
16. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
17. Cruickshank J.M. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ 297 (1988) 1227-1230
18. Cruickshank J.M. The role of coronary perfusion pressure. Eur Heart J 13 Suppl D (1992) 39-43
19. Cruickshank J.M. J curve in antihypertensive therapy-does it exist? A personal point of view. Cardiovasc Drugs Ther 8 (1994) 757-760
20. Cruickshank J.M. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther 14 (2000) 373-379
21. Lee T.T., Chen J., Cohen D.J., and Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 151 (2006) 76-83
22. Owens P., and O'Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events?. Heart 82 (1999) 477-481
23. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
24. Goyal D., Macfadyen R.J., Watson R.D., and Lip G.Y. Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Fail 7 (2005) 149-156
25. Jamieson M.J., and Jamieson C. Ambulatory blood pressure in heart failure. Eur J Clin Invest 31 Suppl 2 (2001) 18-25
26. Canesin M.F., Giorgi D., Oliveira Jr. M.T., Wajngarten M., Mansur A.J., Ramires J.A., et al. Ambulatory blood pressure monitoring of patients with heart failure. A new prognosis marker. Arq Bras Cardiol 78 (2002) 83-89
27. Mosterd A., Cost B., Hoes A.W., de Bruijne M.C., Deckers J.W., Hofman A., et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 22 (2001) 1318-1327
28. Cowie M.R. The prognosis of heart failure: the view from the real world. Eur Heart J 22 (2001) 1247-1248